Press "Enter" to skip to content

U.S. group says Novartis MS drug price out of line with benefit

The Boston-based Institute for Clinical and Economic Review (ICER), which has been reviewing Mayzent for months, recommended that Novartis lower the drug’s price.

Original source: https://health.economictimes.indiatimes.com/news/pharma/u-s-group-says-novartis-ms-drug-price-out-of-line-with-benefit/69889681?utm_source=RSS&utm_medium=ETRSS

Also Read:   Cipla to acquire 11.71% stake in Wellthy Therapeutics